Literature DB >> 19277881

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.

Richard M Martin1, Lars Vatten, David Gunnell, Pål Romundstad, Tom I L Nilsen.   

Abstract

BACKGROUND: The metabolic syndrome has been suggested as a unifying link between a "western" lifestyle and an increased prostate cancer risk.
METHODS: We assessed the associations of components of the metabolic syndrome with prostate cancer in a prospective cohort based on 29,364 Norwegian men followed up for prostate cancer incidence and mortality from 1995-1997 to the end of 2005 in the second Nord Trøndelag Health Study (HUNT 2).
RESULTS: During a mean 9.3 years follow-up, 687 incident prostate cancers were diagnosed, and 110 men died from prostate cancer. There was little evidence that baseline BMI, waist circumference, waist-hip ratio, total or HDL-cholesterol, triglycerides, presence of the metabolic syndrome, diabetes, antihypertensive use, or cardiovascular disease were associated with incident or fatal prostate cancer. There was weak evidence that raised blood pressure was associated with an increased risk: for each SD (12 mm) increase in diastolic blood pressure, there was an 8% (95% CI = 1-17%; p = 0.04) increased risk of incident prostate cancer.
CONCLUSIONS: We found little evidence to support the hypothesis that the metabolic syndrome or its components explains higher prostate cancer mortality rates in countries with a "western" diet and lifestyle. The positive association of blood pressure with prostate cancer warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277881     DOI: 10.1007/s10552-009-9319-x

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  41 in total

1.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice.

Authors:  C Alicia Traughber; Emmanuel Opoku; Gregory Brubaker; Jennifer Major; Hanxu Lu; Shuhui Wang Lorkowski; Chase Neumann; Aimalie Hardaway; Yoon-Mi Chung; Kailash Gulshan; Nima Sharifi; J Mark Brown; Jonathan D Smith
Journal:  J Biol Chem       Date:  2020-05-01       Impact factor: 5.157

Review 3.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

5.  The association between hypertension and prostate cancer.

Authors:  Shah Navin; Vladimir Ioffe
Journal:  Rev Urol       Date:  2017

Review 6.  Risk-based prostate cancer screening: who and how?

Authors:  Allison S Glass; K Clint Cary; Matthew R Cooperberg
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

7.  Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy?

Authors:  Onur Telli; Hasmet Sarici; Musa Ekici; Berat Cem Ozgur; Omer Gokhan Doluoglu; Muzaffer Eroglu; Tugba Akin Telli
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

8.  Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Authors:  Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal
Journal:  BJU Int       Date:  2014-10-20       Impact factor: 5.588

Review 9.  Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.

Authors:  K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano
Journal:  J Endocrinol Invest       Date:  2013-02       Impact factor: 4.256

10.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.